

# Wendy Stock

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6391090/publications.pdf>

Version: 2024-02-01

232  
papers

12,425  
citations

50276

46  
h-index

27406

106  
g-index

234  
all docs

234  
docs citations

234  
times ranked

12565  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.   | 27.0 | 1,161     |
| 2  | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37. | 1.4  | 1,117     |
| 3  | Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 740-753.   | 27.0 | 1,047     |
| 4  | TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.  | 27.0 | 663       |
| 5  | Gene expression changes associated with progression and response in chronic myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2794-2799.   | 7.1  | 525       |
| 6  | What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. <i>Blood</i> , 2008, 112, 1646-1654.              | 1.4  | 479       |
| 7  | PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.   | 21.4 | 384       |
| 8  | Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i> , 2010, 116, 3751-3757.   | 1.4  | 348       |
| 9  | High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2017, 35, 394-401.   | 1.6  | 326       |
| 10 | A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.   | 1.4  | 292       |
| 11 | MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 652-665.   | 16.8 | 274       |
| 12 | Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016, 48, 1481-1489.  | 21.4 | 231       |
| 13 | Adult acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 1165-1176.  | 4.1  | 225       |
| 14 | Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.   | 12.8 | 218       |
| 15 | Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <i>Haematologica</i> , 2014, 99, 1373-1379.  | 3.5  | 213       |
| 16 | Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <i>Leukemia and Lymphoma</i> , 2011, 52, 2237-2253.   | 1.3  | 198       |
| 17 | High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 676-683.  | 1.6  | 171       |
| 18 | Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. <i>Lancet Oncology</i> , 2020, 21, 421-435.                                     | 10.7 | 167       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. <i>Blood</i> , 2011, 118, 6438-6445.   | 1.4  | 158       |
| 20 | Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. <i>Journal of Clinical Oncology</i> , 2005, 23, 3404-3411.                                   | 1.6  | 143       |
| 21 | Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.  | 9.4  | 137       |
| 22 | How I treat acute lymphoblastic leukemia in older adolescents and young adults. <i>Blood</i> , 2015, 125, 3702-3710.  | 1.4  | 121       |
| 23 | P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010, 116, 1413-1421.                            | 1.4  | 113       |
| 24 | Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 725.   | 7.1  | 111       |
| 25 | A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015, 125, 680-686.   | 1.4  | 110       |
| 26 | Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2013, 119, 90-98.   | 4.1  | 104       |
| 27 | Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. <i>Blood Advances</i> , 2017, 1, 1167-1180.  | 5.2  | 103       |
| 28 | Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. <i>Nature Communications</i> , 2021, 12, 1334.   | 12.8 | 103       |
| 29 | Adolescents and Young Adults with Acute Lymphoblastic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 21-29.   | 2.5  | 100       |
| 30 | Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). <i>Haematologica</i> , 2014, 99, 111-115.                                    | 3.5  | 94        |
| 31 | Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2846-2867.  | 9.4  | 83        |
| 32 | Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. <i>Blood</i> , 2014, 124, 796-796.  | 1.4  | 83        |
| 33 | Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123. | 2.0  | 77        |
| 34 | Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 312-320.                                      | 2.5  | 75        |
| 35 | Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021, 2, 284-299.   | 13.2 | 70        |
| 36 | Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 7095-7101.  | 7.0  | 67        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. <i>Oncotarget</i> , 2016, 7, 68833-68841.   | 1.8  | 67        |
| 38 | Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. <i>Blood Advances</i> , 2019, 3, 3488-3498.   | 5.2  | 62        |
| 39 | Psychological morbidities in adolescent and young adult blood cancer patients during curative intent therapy and early survivorship. <i>Cancer</i> , 2016, 122, 954-961.   | 4.1  | 60        |
| 40 | Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2009, 115, 5490-5498.   | 4.1  | 57        |
| 41 | Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. <i>Oncotarget</i> , 2014, 5, 12371-12382.  | 1.8  | 56        |
| 42 | Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. <i>Leukemia and Lymphoma</i> , 2014, 55, 1523-1532.   | 1.3  | 55        |
| 43 | Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.  | 2.0  | 53        |
| 44 | Treatment-influenced associations of PML-RAR1 mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. <i>Blood</i> , 2012, 120, 2098-2108.  | 1.4  | 52        |
| 45 | A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 4.   | 17.0 | 52        |
| 46 | Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study. <i>Blood</i> , 2020, 136, 4-5.                                      | 1.4  | 52        |
| 47 | FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2012, 59, 662-667.  | 1.5  | 48        |
| 48 | Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 431-440.e13.   | 0.4  | 46        |
| 49 | Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. <i>Leukemia and Lymphoma</i> , 2016, 57, 2298-2306. | 1.3  | 45        |
| 50 | Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.  | 5.2  | 44        |
| 51 | SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.                                     | 1.6  | 44        |
| 52 | Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. <i>Cancer</i> , 2018, 124, 1722-1732.   | 4.1  | 43        |
| 53 | Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study. <i>Blood</i> , 2018, 132, 763-763.                                  | 1.4  | 43        |
| 54 | Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL. <i>Blood</i> , 2019, 133, 1715-1719.   | 1.4  | 39        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. <i>Cancer</i> , 2017, 123, 122-130.  | 4.1 | 38        |
| 56 | Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 299-308.  | 0.9 | 38        |
| 57 | Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 449-457.   | 5.2 | 37        |
| 58 | Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Chromosome Negative B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 33-33.   | 1.4 | 37        |
| 59 | Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013, 122, 3903-3903.  | 1.4 | 35        |
| 60 | Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. <i>Blood</i> , 2022, 139, 2212-2226.   | 1.4 | 34        |
| 61 | Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 132-144.   | 2.3 | 31        |
| 62 | Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance). <i>Blood</i> , 2014, 124, 8-8.   | 1.4 | 31        |
| 63 | A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 859-864.   | 2.3 | 30        |
| 64 | Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. <i>Haematologica</i> , 2016, 101, 634-643.  | 3.5 | 30        |
| 65 | Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.   | 4.1 | 30        |
| 66 | Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 614-622.   | 1.3 | 29        |
| 67 | Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.   | 5.2 | 28        |
| 68 | Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085. | 7.2 | 28        |
| 69 | High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. <i>Leukemia Research</i> , 2011, 35, 329-333.   | 0.8 | 27        |
| 70 | Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. <i>Leukemia Research</i> , 2020, 95, 106385.   | 0.8 | 26        |
| 71 | Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. <i>Blood Advances</i> , 2019, 3, 1858-1867.  | 5.2 | 25        |
| 72 | WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2018, 7, 1.   | 5.0 | 24        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. <i>Current Treatment Options in Oncology</i> , 2020, 21, 57.  | 3.0 | 24        |
| 74 | Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.   | 1.4 | 24        |
| 75 | First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 497-497.   | 1.4 | 23        |
| 76 | Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. <i>Blood</i> , 2015, 126, 337-337.   | 1.4 | 23        |
| 77 | T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 33410-33425.  | 1.8 | 22        |
| 78 | Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 188-198.  | 1.3 | 21        |
| 79 | High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). <i>Leukemia and Lymphoma</i> , 2012, 53, 445-450.   | 1.3 | 20        |
| 80 | Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1065-1072.  | 2.0 | 20        |
| 81 | Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2127-2133.  | 1.3 | 20        |
| 82 | Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.  | 2.0 | 20        |
| 83 | The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. <i>Blood</i> , 2021, 138, 1870-1884.   | 1.4 | 20        |
| 84 | Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). <i>Translational Oncology</i> , 2015, 8, 368-375.  | 3.7 | 19        |
| 85 | Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). <i>Leukemia and Lymphoma</i> , 2017, 58, 950-958.  | 1.3 | 18        |
| 86 | Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 997-1004. | 2.0 | 18        |
| 87 | Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. <i>Blood</i> , 2008, 112, 2809-2809.  | 1.4 | 18        |
| 88 | A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage. <i>Blood</i> , 2014, 124, 2255-2255.   | 1.4 | 18        |
| 89 | Children, Adolescents, and Young Adults With Leukemia: The Empty Half of the Glass Is Growing. <i>Journal of Clinical Oncology</i> , 2012, 30, 4037-4038.   | 1.6 | 17        |
| 90 | Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: Characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. <i>Leukemia Research</i> , 2014, 38, 1091-1096.   | 0.8 | 17        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS ONE, 2019, 14, e0224097.  | 2.5  | 17        |
| 92  | Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.  | 12.8 | 17        |
| 93  | Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!. JCO Oncology Practice, 2022, 18, 479-487.   | 2.9  | 17        |
| 94  | Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leukemia and Lymphoma, 2010, 51, 995-1006.   | 1.3  | 16        |
| 95  | Progress in adult ALL: incorporation of new agents to frontline treatment. Hematology American Society of Hematology Education Program, 2017, 2017, 28-36.   | 2.5  | 15        |
| 96  | Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 865-865.  | 1.4  | 15        |
| 97  | Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole. Antimicrobial Agents and Chemotherapy, 2018, 62, .   | 3.2  | 14        |
| 98  | Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatric Blood and Cancer, 2019, 66, e27542.   | 1.5  | 14        |
| 99  | Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies. Blood, 2018, 132, 559-559.  | 1.4  | 14        |
| 100 | A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701. Blood, 2018, 132, 309-309.                | 1.4  | 14        |
| 101 | Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 2491-2491. | 1.4  | 14        |
| 102 | Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.  | 1.4  | 14        |
| 103 | Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Journal of Adolescent and Young Adult Oncology, 2011, 1, 107-108.   | 1.3  | 13        |
| 104 | Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial. Blood, 2018, 132, 287-287.  | 1.4  | 13        |
| 105 | A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Investigational New Drugs, 2008, 26, 331-338.  | 2.6  | 12        |
| 106 | Response: Disparity in outcome of young adults with ALL. Blood, 2009, 113, 1862-1862.  | 1.4  | 12        |
| 107 | De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest, 2017, 152, 683-685.  | 0.8  | 12        |
| 108 | Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leukemia and Lymphoma, 2008, 49, 531-537.                     | 1.3  | 11        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2015, 39, 1437-1442.  | 0.8 | 11        |
| 110 | Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. <i>American Journal of Hematology</i> , 2019, 94, 408-416.  | 4.1 | 11        |
| 111 | Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020, 55, 1161-1168. | 2.4 | 11        |
| 112 | SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 725-733.  | 0.4 | 11        |
| 113 | Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 3415-3415.  | 1.4 | 11        |
| 114 | Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. <i>Blood</i> , 2004, 104, 1145-1145.  | 1.4 | 11        |
| 115 | Results From the Dose Escalation Phase of a Randomized Phase 1 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. <i>Blood</i> , 2012, 120, 414-414.  | 1.4 | 11        |
| 116 | A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 129-132.   | 1.5 | 10        |
| 117 | Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.  | 1.3 | 10        |
| 118 | Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.20.01739.  | 1.6 | 10        |
| 119 | Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. <i>Molecular Cell</i> , 2021, 81, 3833-3847.e11.   | 9.7 | 10        |
| 120 | The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004, 104, 264-264.   | 1.4 | 10        |
| 121 | Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. <i>International Journal of Oncology</i> , 2006, 28, 1099-103.  | 3.3 | 10        |
| 122 | Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4085-4092.   | 5.2 | 10        |
| 123 | Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. <i>Leukemia and Lymphoma</i> , 2016, 57, 1807-1813.   | 1.3 | 9         |
| 124 | A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 599-606.  | 5.2 | 9         |
| 125 | Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. <i>Blood Advances</i> , 2021, 5, 4691-4700.   | 5.2 | 9         |
| 126 | Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3906-3906.   | 1.4 | 9         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. <i>Journal of Clinical Oncology</i> , 2022, 40, 3709-3718.   | 1.6 | 9         |
| 128 | Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial. <i>Blood</i> , 2019, 134, 175-175.   | 1.4 | 8         |
| 129 | Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. <i>Blood</i> , 2013, 122, 825-825.   | 1.4 | 8         |
| 130 | Controversies in Treatment of AML: Case-based Discussion. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 185-191.   | 2.5 | 7         |
| 131 | Incorporating measurable (â€˜minimalâ€™™) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1527-1533.  | 1.3 | 7         |
| 132 | Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. <i>Blood</i> , 2011, 118, 258-258.   | 1.4 | 7         |
| 133 | Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 636-647.  | 0.4 | 6         |
| 134 | Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2020, 10, CD013399.   | 2.8 | 6         |
| 135 | Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). <i>Blood</i> , 2018, 132, 146-146.   | 1.4 | 6         |
| 136 | The Persistence of Minimal Residual Disease in Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1913-1914.  | 2.0 | 5         |
| 137 | OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 48.   | 6.2 | 5         |
| 138 | Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials. <i>Blood</i> , 2018, 132, 2699-2699.  | 1.4 | 5         |
| 139 | Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2018, 132, 3966-3966.   | 1.4 | 5         |
| 140 | Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019, 134, 261-261. | 1.4 | 5         |
| 141 | A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.. <i>Blood</i> , 2004, 104, 873-873.  | 1.4 | 5         |
| 142 | Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.. <i>Blood</i> , 2005, 106, 1833-1833.   | 1.4 | 5         |
| 143 | High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2015, 126, 2618-2618.   | 1.4 | 5         |
| 144 | Optimizing use of L-asparaginaseâ€“based treatment of adults with acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2022, 53, 100908.  | 5.7 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3433-3439.  | 5.2 | 5         |
| 146 | CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the philadelphia chromosome. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 141-144.  | 2.8 | 4         |
| 147 | Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 629-638.  | 1.3 | 4         |
| 148 | Efficacy and tolerability of a modified pediatricâ€inspired intensive regimen for acute lymphoblastic leukemia in older adults. <i>EJHaem</i> , 2021, 2, 413-420.  | 1.0 | 4         |
| 149 | Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2018, 132, 231-231.           | 1.4 | 4         |
| 150 | Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2246-2246.  | 1.4 | 4         |
| 151 | CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 2630-2630.   | 1.4 | 4         |
| 152 | Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). <i>Blood</i> , 2012, 120, 44-44.  | 1.4 | 4         |
| 153 | Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. <i>Blood</i> , 2014, 124, 1093-1093.  | 1.4 | 4         |
| 154 | First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2014, 124, 529-529. | 1.4 | 4         |
| 155 | Philadelphia Chromosomeâ€Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>JCO Oncology Practice</i> , 2020, 16, 231-238.   | 2.9 | 4         |
| 156 | Treating the younger adult with acute lymphoblastic leukemia. <i>Clinical Practice (London, England)</i> , 2012, 9, 439-449.  | 0.1 | 4         |
| 157 | Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 487-8.   | 0.3 | 4         |
| 158 | Looking Toward the Future: Novel Strategies Based on Molecular Pathogenesis of Acute Lymphoblastic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1099-1119.   | 2.2 | 3         |
| 159 | Acute Lymphoblastic Leukemia. <i>Pediatric Oncology</i> , 2017, , 151-175.  | 0.5 | 3         |
| 160 | New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 424-435.  | 2.3 | 3         |
| 161 | A multiâ€institutional comparison of mitoxantrone, etoposide, and cytarabine vs highâ€dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 937-943.  | 4.1 | 3         |
| 162 | A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1397-1397.  | 1.4 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases. <i>Blood</i> , 2018, 132, 2984-2984.  | 1.4 | 3         |
| 164 | Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. <i>Blood</i> , 2019, 134, 1344-1344.  | 1.4 | 3         |
| 165 | Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors. <i>Blood</i> , 2019, 134, 4176-4176.  | 1.4 | 3         |
| 166 | Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration. <i>Blood</i> , 2019, 134, 2957-2957.  | 1.4 | 3         |
| 167 | Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2020, 136, 27-30.   | 1.4 | 3         |
| 168 | Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001). <i>Blood</i> , 2013, 122, 2653-2653.   | 1.4 | 3         |
| 169 | Marqibo® <sup>®</sup> , Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population. <i>Blood</i> , 2015, 126, 1291-1291.  | 1.4 | 3         |
| 170 | Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001. <i>Blood</i> , 2011, 118, 2541-2541.   | 1.4 | 3         |
| 171 | Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2518-2518.  | 1.4 | 3         |
| 172 | Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 144-151.  | 2.3 | 2         |
| 173 | Should immunologic strategies be incorporated into frontline ALL therapy?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 367-372.  | 1.7 | 2         |
| 174 | Acute Lymphoblastic Leukemia in Adults. , 2018, , 1029-1054.e2.  |     | 2         |
| 175 | Philadelphia chromosome-like acute lymphocytic leukemia: Perspectives on diagnosis. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e69.   | 0.9 | 2         |
| 176 | Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2019, , .  | 2.8 | 2         |
| 177 | Thrombosis in ALL: a risk without clear mitigation. <i>Blood</i> , 2020, 136, 264-265.   | 1.4 | 2         |
| 178 | Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1956-1956.  | 1.4 | 2         |
| 179 | Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response. <i>Blood</i> , 2019, 134, 3846-3846. | 1.4 | 2         |
| 180 | Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial. <i>Blood</i> , 2019, 134, 373-373.  | 1.4 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results. <i>Blood</i> , 2020, 136, 41-42.  | 1.4 | 2         |
| 182 | Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS.. <i>Blood</i> , 2007, 110, 1076-1076.  | 1.4 | 2         |
| 183 | Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance). <i>Blood</i> , 2013, 122, 3002-3002.   | 1.4 | 2         |
| 184 | The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago. <i>Blood</i> , 2014, 124, 2509-2509.   | 1.4 | 2         |
| 185 | The Role of Structural Violence in Acute Myeloid Leukemia Outcomes. <i>Blood</i> , 2020, 136, 10-10.   | 1.4 | 2         |
| 186 | Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. <i>Journal of Assisted Reproduction and Genetics</i> , 0, , .   | 2.5 | 2         |
| 187 | Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. <i>Leukemia and Lymphoma</i> , 1991, 4, 145-148.   | 1.3 | 1         |
| 188 | Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population. <i>Blood</i> , 2018, 132, 2245-2245.  | 1.4 | 1         |
| 189 | Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial. <i>Blood</i> , 2019, 134, 2145-2145. | 1.4 | 1         |
| 190 | Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. <i>Blood</i> , 2005, 106, 2022-2022.  | 1.4 | 1         |
| 191 | Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. <i>Blood</i> , 2008, 112, 3015-3015.  | 1.4 | 1         |
| 192 | Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012, 120, 3535-3535.                            | 1.4 | 1         |
| 193 | DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. <i>Blood</i> , 2013, 122, 1548-1548.                                     | 1.4 | 1         |
| 194 | Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance). <i>Blood</i> , 2013, 122, 2547-2547.  | 1.4 | 1         |
| 195 | Suffering Before The Cure: Evaluation Of Psychological Morbidities In Adolescents and Young Adults With Hematologic Malignancies In Early Survivorship. <i>Blood</i> , 2013, 122, 771-771.   | 1.4 | 1         |
| 196 | Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance). <i>Blood</i> , 2014, 124, 2301-2301.   | 1.4 | 1         |
| 197 | A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL). <i>Blood</i> , 2015, 126, 4866-4866.                         | 1.4 | 1         |
| 198 | Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 693-693.   | 1.4 | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | WT1 Peptide Vaccine Is Able to Induce WT1-Specific Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3984-3984.  | 1.4 | 1         |
| 200 | Anti-Angiogenic Effects of Sorafenib in Relapsed Chronic Lymphocytic Leukemia: Correlative Studies of a Phase 2 Clinical Trial.. <i>Blood</i> , 2007, 110, 4726-4726.  | 1.4 | 1         |
| 201 | Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies. <i>Blood</i> , 2011, 118, 830-830.   | 1.4 | 1         |
| 202 | A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance). <i>Blood</i> , 2014, 124, 2306-2306.  | 1.4 | 1         |
| 203 | Evaluation of Romylocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy. <i>Blood</i> , 2018, 132, 1407-1407.  | 1.4 | 1         |
| 204 | Higher Socioeconomic Status Is Associated with Improved Overall Survival in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: A Population Study. <i>Blood</i> , 2018, 132, 4780-4780.  | 1.4 | 1         |
| 205 | Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study). <i>Blood</i> , 2021, 138, 2344-2344.              | 1.4 | 1         |
| 206 | Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.. <i>Blood</i> , 2005, 106, 1818-1818.   | 1.4 | 0         |
| 207 | Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).. <i>Blood</i> , 2006, 108, 4539-4539.   | 1.4 | 0         |
| 208 | Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. <i>Blood</i> , 2006, 108, 1952-1952.  | 1.4 | 0         |
| 209 | New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2006, 108, 3675-3675.   | 1.4 | 0         |
| 210 | Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoietic Stem Cell Transplants.. <i>Blood</i> , 2007, 110, 1973-1973.  | 1.4 | 0         |
| 211 | Unrelated Donor (URD) Searches in African-Americans with Hematologic Malignancies: Paucity of HLA Identical Donors.. <i>Blood</i> , 2007, 110, 5064-5064.  | 1.4 | 0         |
| 212 | Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study. <i>Blood</i> , 2011, 118, 1948-1948.   | 1.4 | 0         |
| 213 | A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 496-496. | 1.4 | 0         |
| 214 | Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo® (vinCRISTine sulfate LIPOSOME injection). <i>Blood</i> , 2012, 120, 4805-4805.   | 1.4 | 0         |
| 215 | Growth Inhibitory Function Of a Novel T-LAK Cell-Originated Protein Kinase Inhibitor On FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cells. <i>Blood</i> , 2013, 122, 1459-1459.   | 1.4 | 0         |
| 216 | Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1398-1398.  | 1.4 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2463-2463.  | 1.4 | 0         |
| 218 | Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA). <i>Blood</i> , 2014, 124, 2464-2464.                                      | 1.4 | 0         |
| 219 | Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3777-3777.   | 1.4 | 0         |
| 220 | Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18537-e18537.   | 1.6 | 0         |
| 221 | Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). <i>Blood</i> , 2018, 132, 2767-2767.  | 1.4 | 0         |
| 222 | Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 4073-4073.  | 1.4 | 0         |
| 223 | Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7029-7029.       | 1.6 | 0         |
| 224 | Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients. <i>Blood</i> , 2019, 134, 1319-1319.              | 1.4 | 0         |
| 225 | Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML. <i>Blood</i> , 2019, 134, 3413-3413.   | 1.4 | 0         |
| 226 | Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. <i>Blood</i> , 2019, 134, 3324-3324.   | 1.4 | 0         |
| 227 | The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression. <i>Blood</i> , 2019, 134, 2748-2748.   | 1.4 | 0         |
| 228 | Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome. <i>Blood</i> , 2020, 136, 35-36.   | 1.4 | 0         |
| 229 | D-Dimer As a Predictor of Thrombotic Events during Early Acute Lymphoblastic Leukemia Therapy. <i>Blood</i> , 2020, 136, 5-6.   | 1.4 | 0         |
| 230 | Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT). <i>Blood</i> , 2020, 136, 39-40. | 1.4 | 0         |
| 231 | Pediatric regimens for adult acute lymphoblastic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 244-6.  | 0.3 | 0         |
| 232 | Treatment of acute lymphoblastic leukemia (ALL) in adults. , 2010, , 43-67.   |     | 0         |